Payment overview · 2025
General Payments
$1,309.79
72 reported records · 23 companies
Healthcare provider profile · identity verified
Jeffrey M Saylor, MD
Allopathic & Osteopathic Physicians|Family Medicine · GUNTERSVILLE, AL · NPI 1174589410
Verified facts
What the public records show
CMS Open Payments records show Jeffrey M Saylor, MD received $1,309.79 in general payments during 2025 across 72 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1434 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Lantus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $245.65 | 18.8% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.91 | 13.3% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $116.71 | 8.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.11 | 5.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.79 | 5.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $75.84 | 5.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.79 | 5.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.48 | 4.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $50.23 | 3.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.21 | 3.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.25 | 3.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $35.74 | 2.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.31 | 2.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.61 | 2.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.30 | 2.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.50 | 1.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.33 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.00 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.21 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.45 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.49 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.93 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.95 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,309.79 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $133.34 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $116.71 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.35 | 5 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $88.59 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.79 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $75.84 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $73.88 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.65 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.62 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.99 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.46 | 5 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $56.05 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.48 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $50.23 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $43.25 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.71 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.57 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $35.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.61 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 18 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1434 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 271 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
271 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
271 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1434 | 101 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
52 | 48 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2924 | 222 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2241 | 215 |
| Potassium Chloride | Potassium Chloride | 1949 | 127 |
| Omeprazole | Omeprazole | 1813 | 162 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1792 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 1789 | 172 |
| Eliquis | Apixaban | 1434 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 1396 | 149 |
| Furosemide | Furosemide | 1343 | 134 |
| Trazodone Hcl | Trazodone Hcl | 1189 | 96 |
| Losartan Potassium | Losartan Potassium | 1147 | 119 |
| Sertraline Hcl | Sertraline Hcl | 1109 | 62 |
| Donepezil Hcl | Donepezil Hcl | 1055 | 50 |
| Mirtazapine | Mirtazapine | 957 | 54 |
| Buspirone Hcl | Buspirone Hcl | 953 | 59 |
| Lisinopril | Lisinopril | 884 | 113 |
| Escitalopram Oxalate | Escitalopram Oxalate | 837 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 828 | 128 |
| Gabapentin | Gabapentin | 823 | 113 |
| Tamsulosin Hcl | Tamsulosin Hcl | 811 | 91 |
| Memantine Hcl | Memantine Hcl | 797 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 720 | 55 |
| Metformin Hcl | Metformin Hcl | 704 | 98 |
| Ropinirole Hcl | Ropinirole Hcl | 573 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 535 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 523 | 45 |
| Montelukast Sodium | Montelukast Sodium | 515 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 487 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 484 | 75 |
| Famotidine | Famotidine | 462 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 457 | 53 |
| Sucralfate | Sucralfate | 452 | 46 |
| Spironolactone | Spironolactone | 448 | 40 |
| Baclofen | Baclofen | 441 | 46 |
| Simvastatin | Simvastatin | 441 | 49 |
| Carvedilol | Carvedilol | 432 | 44 |
| Divalproex Sodium | Divalproex Sodium | 426 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 417 | 59 |
| Tramadol Hcl | Tramadol Hcl | 415 | 74 |
| Allopurinol | Allopurinol | 391 | 30 |
| Azithromycin | Azithromycin | 390 | 278 |
| Meloxicam | Meloxicam | 387 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 384 | 55 |
| Risperidone | Risperidone | 378 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 363 | 70 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 360 | 22 |
| Alprazolam | Alprazolam | 356 | 57 |
| Fluoxetine Hcl | Fluoxetine Hcl | 340 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 310 | 26 |
| Clonazepam | Clonazepam | 309 | 41 |
| Torsemide | Torsemide | 303 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 298 | 22 |
| Prednisone | Prednisone | 279 | 95 |
| Myrbetriq | Mirabegron | 273 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 273 | 12 |
| Jardiance | Empagliflozin | 271 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 268 | 80 |
| Pregabalin | Pregabalin | 238 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 232 | 19 |
| Cephalexin | Cephalexin | 229 | 66 |
| Amiodarone Hcl | Amiodarone Hcl | 228 | 21 |
| Levetiracetam | Levetiracetam | 222 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 220 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 212 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 206 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 200 | 131 |
| Aripiprazole | Aripiprazole | 196 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 178 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 174 | suppressed |
| Ezetimibe | Ezetimibe | 170 | 16 |
| Ranolazine Er | Ranolazine | 170 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 169 | 27 |
| Primidone | Primidone | 168 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 167 | suppressed |
| Olanzapine | Olanzapine | 166 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 64 |
| Oxybutynin Chloride | Oxybutynin Chloride | 159 | suppressed |
| Levofloxacin | Levofloxacin | 154 | 96 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 154 | 68 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 19 |
| Fluconazole | Fluconazole | 149 | 82 |
| Xarelto | Rivaroxaban | 149 | 12 |
| Temazepam | Temazepam | 147 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 146 | 114 |
| Clonidine Hcl | Clonidine Hcl | 142 | 32 |
| Lansoprazole | Lansoprazole | 138 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 135 | 24 |
| Methocarbamol | Methocarbamol | 134 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 128 | suppressed |
| Lorazepam | Lorazepam | 126 | 28 |
| Valsartan | Valsartan | 119 | 26 |
| Estradiol | Estradiol | 118 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 118 | 21 |
| Ondansetron Odt | Ondansetron | 118 | 47 |
| Digoxin | Digoxin | 116 | suppressed |
| Ozempic | Semaglutide | 112 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 110 | 16 |
| Finasteride | Finasteride | 109 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 108 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 107 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 102 | 14 |
| Synthroid | Levothyroxine Sodium | 101 | 20 |
| Topiramate | Topiramate | 100 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 17 |
| Nystatin | Nystatin | 96 | 56 |
| Methylprednisolone | Methylprednisolone | 95 | 78 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 94 | 11 |
| Atenolol | Atenolol | 94 | 19 |
| Ceftriaxone | Ceftriaxone Sodium | 94 | 56 |
| Glipizide | Glipizide | 94 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 91 | 12 |
| Celecoxib | Celecoxib | 89 | 24 |
| Albuterol Sulfate | Albuterol Sulfate | 88 | 32 |
| Entresto | Sacubitril/Valsartan | 86 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 85 | 62 |
| Mounjaro | Tirzepatide | 84 | 13 |
| Enalapril Maleate | Enalapril Maleate | 82 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 81 | 51 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 81 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 80 | 17 |
| Verapamil Er | Verapamil Hcl | 80 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 79 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 78 | 13 |
| Valacyclovir | Valacyclovir Hcl | 78 | 23 |
| Bupropion Xl | Bupropion Hcl | 77 | suppressed |
| Cefdinir | Cefdinir | 77 | 60 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 73 | 26 |
| Promethazine Hcl | Promethazine Hcl | 73 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 67 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 66 | suppressed |
| Fenofibrate | Fenofibrate | 65 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 65 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 63 | suppressed |
| Eszopiclone | Eszopiclone | 62 | 12 |
| Np Thyroid | Thyroid,pork | 61 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 61 | suppressed |
| Carbamazepine | Carbamazepine | 60 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 60 | suppressed |
| Febuxostat | Febuxostat | 59 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 59 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 11 |
| Armour Thyroid | Thyroid,pork | 54 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 54 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 53 | suppressed |
| Pentoxifylline | Pentoxifylline | 53 | suppressed |
| Glimepiride | Glimepiride | 52 | 11 |
| Megestrol Acetate | Megestrol Acetate | 52 | suppressed |
| Nifedipine | Nifedipine | 52 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 48 |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 51 | suppressed |
| Acetazolamide | Acetazolamide | 50 | suppressed |
| Diazepam | Diazepam | 50 | suppressed |
| Carbamazepine Er | Carbamazepine | 49 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 17 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 40 |
| Bupropion Hcl | Bupropion Hcl | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 12 |
| Vraylar | Cariprazine Hcl | 48 | suppressed |
| Enulose | Lactulose | 46 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 34 |
| Gemtesa | Vibegron | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 15 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Naproxen | Naproxen | 42 | suppressed |
| Olanzapine Odt | Olanzapine | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Etodolac | Etodolac | 41 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Metronidazole | Metronidazole | 40 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Calcium Acetate | Calcium Acetate | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | 12 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 16 |
| Progesterone | Progesterone, Micronized | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 35 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 21 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 32 | 21 |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 13 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Ertapenem | Ertapenem Sodium | 25 | 15 |
| Glyburide | Glyburide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Colchicine | Colchicine | 24 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Humulin R | Insulin Regular, Human | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Hydroxyurea | Hydroxyurea | 22 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Nystop | Nystatin | 22 | 16 |
| Ropinirole Er | Ropinirole Hcl | 22 | suppressed |
| Daptomycin | Daptomycin | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 19 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Nadolol | Nadolol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,309.79 · 72 records | ABBVIE INC. | ABRYSVO, AVYCAZ, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, EMBLAVEO, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, IBSRELA, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, TEFLARO, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error